Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

H Røsjø, Z Hijazi, T Omland, J Westerbergh, M N Lyngbakken, J H Alexander, B J Gersh, C B Granger, E M Hylek, R D Lopes, A Siegbahn, L Wallentin, H Røsjø, Z Hijazi, T Omland, J Westerbergh, M N Lyngbakken, J H Alexander, B J Gersh, C B Granger, E M Hylek, R D Lopes, A Siegbahn, L Wallentin

Abstract

Background: Cardiac troponin T (cTnT) and I (cTnI) concentrations provide strong prognostic information in anticoagulated patients with atrial fibrillation (AF). Whether the associations between cardiac troponin concentrations and mortality and morbidity differ by sex is not known.

Objectives: To assess whether men and women have different concentrations and prognostic value of cTnT and cTnI measurements in anticoagulated patients with AF.

Methods: cTnT and cTnI concentrations were measured with high-sensitivity (hs) assays in EDTA plasma samples obtained from the multicentre ARISTOTLE trial, which randomized patients with AF and at least one risk factor for stroke or systemic embolic event to warfarin or apixaban. Patients were stratified according to sex and the associations between hs-troponin concentrations, and all-cause death, cardiac death, myocardial infarction, stroke or systemic embolic event and major bleeding were assessed in multivariable regression models.

Results: We found higher cardiac troponin concentrations in men (n = 9649) compared to women (n = 5331), both for hs-cTnT (median 11.8 [Q1-3 8.1-18.0] vs. 9.6 [6.7-14.3] ng L-1 , P < 0.001) and hs-cTnI (5.8 [3.4-10.8] vs. 4.9 [3.1-8.8] ng L-1 , P < 0.001). Adjusting for baseline demographics, comorbidities and medications, men still had significantly higher hs-troponin concentrations than women. C-reactive protein and N-terminal pro-B-type natriuretic peptide concentrations were higher in female patients. Both hs-cTnT and hs-cTnI concentrations were associated with all clinical outcomes similarly in men and women (p-value for interaction >0.05 for all end-points).

Conclusion: Men have higher hs-troponin concentrations than women in AF. Regardless of sex, hs-troponin concentrations remain similarly associated with adverse clinical outcomes in anticoagulated patients with AF.

Trial registration: ClinicalTrials.gov NCT00412984.

Keywords: atrial fibrillation; biomarker; gender; prognostication; troponin.

© 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.

References

    1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 50: e1-e88.
    1. Hijazi Z, Wallentin L, Siegbahn A et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014; 63: 52-61.
    1. Hijazi Z, Siegbahn A, Andersson U et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 129: 625-34.
    1. Hijazi Z, Siegbahn A, Andersson U et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem 2015; 61: 368-78.
    1. Thygesen K, Alpert JS, Jaffe AS et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-69.
    1. Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004; 109: 580-6.
    1. Omland T, de Lemos JA, Holmen OL et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. Clin Chem 2015; 61: 646-56.
    1. Lyngbakken MN, Røsjø H, Holmen OL et al. Gender, high-sensitivity troponin I, and the risk of cardiovascular events (from the Nord-Trondelag Health Study). Am J Cardiol 2016; 118: 816-21.
    1. Dallmeier D, Denkinger M, Peter R et al. Sex-specific associations of established and emerging cardiac biomarkers with all-cause mortality in older adults: the ActiFE study. Clin Chem 2015; 61: 389-99.
    1. Eggers KM, Johnston N, Lind L, Venge P, Lindahl B. Cardiac troponin I levels in an elderly population from the community-The implications of sex. Clin Biochem 2015; 48: 751-6.
    1. Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.
    1. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
    1. Saenger AK, Beyrau R, Braun S et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chem Acta 2011; 412: 748-54.
    1. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumable healthy population. Clin Chem 2012; 58: 1574-81.
    1. Hijazi Z, Wallentin L, Siegbahn A et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61: 2274-84.
    1. Wallentin L, Hijazi Z, Andersson U et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 130: 1847-58.
    1. Aulin J, Siegbahn A, Hijazi Z et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 2015; 170: 1151-60.
    1. Pol T, Held C, Westerbergh J et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. J Am Heart Assoc 2018; 7: e007444.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
    1. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2017;. Available at .
    1. Omland T, Røsjø H, Giannitsis E, Agewall S. Troponins in heart failure. Clin Chim Acta 2015; 443: 78-84.
    1. Omland T, de Lemos JA, Sabatine MS et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361: 2538-47.
    1. Omland T, Pfeffer MA, Solomon SD et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013; 61: 1240-9.
    1. de Lemos JA, Drazner MH, Omland T et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-12.
    1. Neeland IJ, Drazner MH, Berry JD et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol 2013; 61: 187-95.
    1. Røsjø H, Andreassen J, Edvardsen T, Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol 2011; 108: 88-91.
    1. Chin CW, Shah AS, McAllister DA et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014; 35: 2312-21.
    1. Laufer EM, Mingels AM, Winkens MH et al. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010; 30: 1269-75.
    1. Myhre PL, Omland T, Sarvari SI et al. Cardiac troponin T concentrations, reversible myocardial ischemia, and indices of left ventricular remodeling in patients with suspected stable angina pectoris: a DOPPLER-CIP substudy. Clin Chem 2018; 64: 1370-9.
    1. Saunders JT, Nambi V, de Lemos JA et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 123: 1367-76.
    1. Salton CJ, Chuang ML, O'Donnell CJ et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002; 39: 1055-60.
    1. Swaanenburg JC, Visser-VanBrummen PJ, DeJongste MJ, Tiebosch AT. The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydroxybutyric acid dehydrogenase in the human heart. Am J Clin Pathol 2001; 115: 770-7.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera